Trial · NCT03935646
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Continuous Performance Test - Identical Pairs (CPT-IP) for Adderall vs. Placebo | Completed at baseline and each experimental appointment over a period of three weeks | The CPT-IP is a standardized computer-administered test consisting of four-digit numbers that are presented for 200ms on a white screen with 1500ms between the presentation of each number. Participants must press the spacebar as quickly as possible when the preceding four-digit number matches the current four-digit number. Participants will complete the CPT-IP as a measure of sustained attention at baseline and at each experimental appointment. |
| Primary | Change in Spatial Span (SS) for Adderall vs. Placebo | Completed at baseline and each experimental appointment over a period of three weeks | The Spatial Span (SS) is a computer-administered task assessing visuospatial working memory. Participants will be tasked with remembering the order of stimuli that are presented in forward and backward sequences. Participants will complete the SS visuospatial working memory task at baseline and at each experimental appointment. |
| Primary | Change in Digit Span for Adderall vs. Placebo | Completed at baseline and each experimental appointment over a period of three weeks | The Digit Span (Wechsler, 2008) subtest of the Wechsler Adult Intelligence Scale (WAIS-IV) is an auditory working memory task. The researcher will say numbers aloud at a rate of one number per second. The participant will be tasked with remembering and repeating the numbers in a prescribed (forward, backward, sequencing) order. Participants will complete the Digit Span (forward, backward and sequencing) auditory working memory task at baseline and at each experimental appointment. |
| Primary | Change in Letter-Number Sequencing for Adderall vs. Placebo | Completed at baseline and each experimental appointment over a period of three weeks | The Letter-Number Sequencing (Wechsler, 2008) task is a supplemental subtest of the Wechsler Adult Intelligence Scale (WAIS-IV) that measures auditory working memory. Researchers will read a sequence of letters and numbers, and the participant will attempt to recall the numbers in ascending order and the letters in alphabetical order. Participants will complete the Letter-Number Sequencing auditory working memory task at baseline and at each experimental appointment. |
| Primary | Visual Analogue Scales (VAS) for Adderall vs. Placebo | two weeks | The VAS is a nine-item questionnaire that assesses subjective mood in the moment including how good, bad, focused, and motivated participants feel. Additionally, participants are asked how well they expect to perform on cognitive tests and how much effort they will put into completing cognitive tests. Participants will complete the VAS at each experimental appointment. |
| Primary | Addiction Research Center Inventory (ARCI) for Adderall vs. Placebo | two weeks | The ARCI is a 49 true-false item measure that assesses drug effects by asking how the participant feels in the moment. Participants will complete the ARCI at each experimental appointment. |
| Primary | Intentions to Use Questionnaire (IUQ) for Adderall vs. Placebo | two weeks | The IUQ is a six-item measure that assesses the likelihood of participants to use substances including prescription stimulants for specific purposes such as for studying or improving academic performance. Participants will complete the IUQ at each experimental appointment. |
| Secondary | Pittsburgh Sleep Quality Index-Modified (PSQI-M) | Completed the day after each experimental appointment over a period of two weeks | The PSQI contains 19 items that evaluates several components of sleep quality by requiring participants to report their sleep behaviors. Participants will receive the survey via text and email the morning after their experimental appointment. They will be instructed to complete the PSQI-M regarding their sleep functioning (i.e., subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction) from "yesterday (from the time after your lab appointment until you went to bed)." |
| Secondary | Depression, Anxiety, and Stress Scale-Modified (DASS-M) | Completed the day after each experimental appointment over a period of two weeks | This scale includes 21 questions to measure current mood and stress levels. Items include a choice of four responses from "Did not apply to me at all," to "Applied to me very much." Participants will receive the survey via text and email the morning after their experimental appointment. They will be instructed to complete the DASS-M regarding their emotional experiences of depression, anxiety, and stress from "yesterday (from the time after your lab appointment until you went to bed)." |
| Secondary | DSM-5 ADHD Symptoms Checklist - Modified (DSM 5-M) | Completed the day after each experimental appointment over a period of two weeks | The DSM 5-M will ask participants about how often they experienced the symptoms of ADHD for the 24 hours from "yesterday (from the time after your lab appointment until you went to bed)" and will be completed following both experimental sessions |
| Secondary | Side Effects Rating Scale - Modified | Completed the day after each experimental appointment over a period of two weeks | The Side Effects Rating Scale - Modified asks participants about behaviors from side effects of ADHD medication for the 24 hours from "yesterday (from the time after your lab appointment until you went to bed)" and will be completed following both experimental sessions |
| Secondary | Substance Use Day After Questionnaire | Completed the day after each experimental appointment over a period of two weeks | This Substance Use Day After Questionnaire asks participants if they engaged in any substance use (including use of alcohol, prescription stimulants, caffeine, cannabis, or other illicit substances) since "yesterday (from the time after your lab appointment until you went to bed)" and will be completed following both experimental sessions |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03935646/registered